(-)Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells

Leukemia and Lymphoma

Volumn 48, Issue 11, 2007, Pages 2204-2212

  Meng, Yang ^a   Li, Yan ^a   Li, Jing ^a   Li, Hongyan ^a   Fu, Jianjiang ^a   Liu, Yue ^a   Liu, He ^a   Chen, Xiaoguang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

( )Gossypol; Apoptosis; Chronic myeloid leukemia; Imatinib

Indexed keywords

CASPASE 3; CYTOCHROME C; GOSSYPOL; IMATINIB; PROTEIN BCL XL; PROTEIN MCL 1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; DRUG POTENCY; DRUG POTENTIATION; ENZYME DEGRADATION; ENZYME RELEASE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

APOPTOSIS; BCL-X PROTEIN; CASPASE 3; CELL PROLIFERATION; CYTOCHROMES C; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; FUSION PROTEINS, BCR-ABL; GOSSYPOL; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; NEOPLASM PROTEINS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIMIDINES;

EID: 36048943429     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701583991     Document Type: Article

References (30)

1. Calabretta, B. and Perrotti, D. (2004) The biology of CML blast crisis. Blood, 103, pp. 4010-4022.
2. Savage, D. G. and Antman, K. H. (2002) Imatinib mesylate - a new oral targeted therapy. N Engl J Med, 346, pp. 683-693.
3. Goldman, J. M., Marin, D., Olavarria, E. and Apperley, J. F. (2003) Clinical decisions for chronic myelogenous leukemia in the imatinib era. Semin Hematol, 40:2, pp. 98-103.
4. (1989) An overview of the clinical pharmacology and therapeutic potential of gossypol as a male contraceptive agent and in gynaecological disease. Drugs, 38, pp. 333-341.
5. Tuszynski, G. P. and Cossu, G. (1984) Differential cytotoxic effect of gossypol on human melanoma, colon carcinoma, and other tissue culture cell lines. Cancer Res, 44, pp. 768-771.
6. Zhang, M., Liu, H., Guo, R. and Ling, Y. (2003) Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem Pharmacol, 66, pp. 93-103.
7. Chang, J. S., Hsu, Y. L., Kuo, P. L., Chiang, L. C. and Lin, C. C. (2004) Upregulation of Fas/Fas ligand-mediated apoptosis by gossypol in an immortalized human alveolar lung cancer cell line. Clin Exp Pharmacol Physiol, 31, pp. 716-722.
8. Liu, S., Kulp, S. K., Sugimoto, Y., Jiang, J., Chang, H. L. and Dowd, M. K. (2002) The (-)-enantiomer of gossypol possesses higher anticancer potency than racemic gossypol in human breast cancer. Anticancer Res, 22, pp. 33-38.
9. Yang, D., Wang, S., Tang, W., Liu, M. and Davis, M. (2005) (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. Mol Cancer Ther, 4, pp. 197-205.
10. Hou, D. X., Uto, T., Tong, X., Takeshita, T., Tanigawa, S. and Imamura, I. (2004) Involvement of reactive oxygen species-independent mitochondrial pathway in gossypol-induced apoptosis. Arch Biochem Biophys, 428, pp. 179-187.
11. Ergun, M. A., Konac, E., Erbas, D. and Ekmekci, A. (2004) Apoptosis and nitric oxide release induced by thalidomide, gossypol and dexamethasone in cultured human chronic myelogenous leukemic K-562 cells. Cell Biol Int, 28, pp. 237-242.
12. Van Poznak, C., Seidman, A. D., Reidenberg, M. M., Moasser, M. M., Sklarin, N. and Van Zee, K. (2001) Oral gossypol in the treatment of patients with refractory metastatic breast cancer: A phase I/II clinical trial. Breast Cancer Res Treat, 66, pp. 239-248.
13. Wang, G., Nikolovska-Coleska, Z., Yang, C. Y., Wang, R., Tang, G. and Guo, J. (2006) Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem, 49, pp. 6139-6142.
14. Qiu, J., Levin, L. R., Buck, J. and Reidenberg, M. M. (2002) Different pathways of cell killing by gossypol enantiomers. Exp Biol Med (Maywood), 227, pp. 398-401.
15. Cho, S. G. and Choi, E. J. (2002) Apoptotic signaling pathways: Caspases and stress-activated protein kinases. J Biochem Mol Biol, 35, pp. 24-27.
16. Keeshan, K., Mills, K. I., Cotter, T. G. and McKenna, S. L. (2001) Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype. Leukemia, 15, pp. 1823-1833.
17. Lahaye, T., Riehm, B., Berger, U., Paschka, P., Muller, M. C. and Kreil, S. (2005) Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: A 4.5-year follow-up. Cancer, 103, pp. 1659-1669.
18. Tauchi, T. and Ohyashiki, K. (2004) Molecular mechanisms of resistance of leukemia to imatinib mesylate. Leuk Res, 28, pp. S39-S45.
19. Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L. and Kuriyan, J. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell, 2, pp. 117-125.
20. Chen, R., Gandhi, V. and Plunkett, W. (2006) A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res, 66, pp. 10959-10966.
21. Hoover, R. R., Mahon, F. X., Melo, J. V. and Daley, G. Q. (2002) Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood, 100, pp. 1068-1071.
22. Radujkovic, A., Topaly, J., Fruehauf, S. and Zeller, W. J. (2006) Combination treatment of imatinib-sensitive and - resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors. Anticancer Res, 26, pp. 2169-2177.
23. Nimmanapalli, R., Fuino, L., Stobaugh, C., Richon, V. and Bhalla, K. (2003) Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood, 101, pp. 3236-3239.
24. Tseng, P. H., Lin, H. P., Zhu, J., Chen, K. F., Hade, E. M. and Young, D. C. (2005) Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. Blood, 105, pp. 4021-4027.
25. Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J. and Belli, B. A. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature, 435, pp. 677-681.
26. Blanc, M Le, Russo, J., Kudelka, A. P. and Smith, J. A. (2002) An in vitro study of inhibitory activity of gossypol, a cottonseed extract, in human carcinoma cell lines. Pharmacol Res, 46, pp. 551-555.
27. Mohammad, R. M., Wang, S., Aboukameel, A., Chen, B. and Chen, J. (2005) Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) (-)-gossypol against diffuse large cell lymphoma. Mol Cancer Ther, 4, pp. 13-21.
28. Mow, B. M., Chandra, J., Svingen, P. A., Hallgren, C. G., Weisberg, E. and Kottke, T. J. (2002) Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood, 99, pp. 664-671.
29. Donato, N. J., Wu, J. Y., Stapley, J., Gallick, G., Lin, H. and Arlinghaus, R. (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood, 101, pp. 690-698.
30. Aichberger, K. J., Mayerhofer, M., Krauth, M. T., Skvara, H., Florian, S. and Sonneck, K. (2005) Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): Evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood, 105, pp. 3303-3311.